Biocon Peer Comparison

NSE: BIOCON | BSE: 532523

₹417.00

₹-0.50 (-0.12%)

As on 27-Aug-2026 11:29IST

Market cap

₹67,844 Cr

Revenue (TTM)

₹17,321 Cr

P/E Ratio

137

P/B Ratio

Div. Yield

0.1 %

Edit

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Market cap (₹ Cr)	67,844	1,14,045	98,596	98,429	98,650
Revenue (₹ Cr)	17,321	28,592	29,967	33,228	14,738
Net Profit (₹ Cr)	416.40	4,492.20	5,551.01	3,169.30	2,055.11
Net Margin (%)	2.36	14.92	18.23	9.15	13.64
RoE (%)	-0.21	18.78	28.32	8.72	13.60
Price to Earnings	136.98	25.27	17.83	30.55	48.29
Price-To-Book	2.00	4.23	4.14	2.58	5.86

Income Statement (₹ Cr)

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Operating Revenue	17,321.10	28,591.70	29,966.58	33,227.90	14,737.88
Total Income	17,638.40	30,111.40	30,442.31	34,650.70	15,061.79
Total Expenditure	13,784.70	21,334.70	20,428.27	28,088.10	10,911.05
EBITDA	3,536.40	7,257.00	9,538.31	5,139.80	3,826.83
Depreciation	2,049.10	1,724.60	1,529.37	2,119.30	893.20
EBIT	1,487.30	5,532.40	8,008.94	3,020.50	2,933.63
Interest	926.80	510.20	452.37	416.30	578.61
Other Income	317.30	1,519.70	475.73	1,422.80	323.91
Exceptional Items	-399.20	-534.80	-557.91	0.00	-129.75
Profit before Tax	478.60	6,007.10	7,474.39	4,027.00	2,549.18
Provision for Tax	62.20	1,514.90	1,923.38	857.70	494.07
Profit after Tax	416.40	4,492.20	5,551.01	3,169.30	2,055.11

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Shareholder's Funds	34,031.80	27,111.40	22,448.27	37,891.50	16,300.34
Minority Interest	78.90	-79.70	-22.18	38.90	-24.90
Non-Current Liabilities	12,959.90	7,112.50	3,200.22	3,145.10	5,011.23
Current Liabilities	14,069.20	15,711.90	12,651.24	16,747.40	6,507.25
Total Liabilities	63,408.90	50,672.60	38,146.06	56,576.70	27,754.83

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Non-Current Assets	44,539.50	31,677.20	11,888.82	27,204.00	20,274.65
Current Assets	17,179.80	19,906.10	24,027.38	30,179.30	6,954.20
Total Assets	63,408.90	50,672.60	38,146.06	56,576.70	27,754.83
Total Debt*	14,824.70	11,769.50	5,910.20	7,734.10	6,021.78
Net Current Assets	3,110.60	4,194.20	11,376.14	13,431.90	446.95
Contingent Liabilities	928.40	989.90	1,094.02	336.14	924.77

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Cash From Operating Activities	1,994.00	2,116.60	7,334.50	5,673.70	3,121.29
Cash Flow from Investing Activities	-2,082.10	-8,296.10	-3,864.59	-6,549.30	-196.42
Cash from Financing Activities	-923.60	5,806.90	-845.87	829.00	-2,952.69
Net Cash Inflow / Outflow	-1,011.70	-372.60	2,624.04	-46.60	-27.82

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
ROCE (%)	3.26	21.39	28.86	13.75	13.24
ROE (%)	-0.21	18.78	28.32	8.72	13.60
ROA (%)	0.68	10.03	16.43	5.89	7.36
EBIT Margin (%)	8.59	19.35	26.73	9.09	19.91
Net Margin (%)	2.36	14.92	18.23	9.15	13.64
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Revenue Growth (%)	9.83	21.11	28.19	-0.87	14.16
EBIT Growth (%)	-3.73	-8.99	77.03	-55.06	19.45
Net Profit Growth (%)	-36.60	-3.14	49.13	-44.66	8.09
EPS Growth (%)	-129.45	4.31	60.86	-43.29	12.27
Book Value Growth (%)	57.96	13.19	30.75	12.99	13.74

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Price / Earnings	-455.42	23.43	16.81	30.73	45.99
Price / Book Value	2.00	4.25	4.21	2.59	5.87
Dividend Yield (%)	0.12	0.09	0.82	0.67	0.04
EV/EBITDA	22.33	16.41	10.16	19.41	26.87
Market Cap (₹ Cr)	58,492.94	87,643.18	1,05,737.27	1,04,763.81	82,801.75

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Debt to Equity	0.32	0.12	0.07	0.00	0.17
Short term debt to equity ratio	0.10	0.16	0.18	0.16	0.04
Current Ratio	1.22	1.27	1.90	1.80	1.07
Quick Ratio	0.79	0.91	1.42	1.35	0.74
Interest Coverage	1.52	12.77	17.52	10.67	5.41

	Biocon	Zydus Lifesciences	Lupin	Dr. Reddy'S Labs	Mankind Pharma
Debtors to sales (%)	34.56	18.94	22.04	30.47	11.74
Asset Turnover	0.28	0.64	0.89	0.62	0.53
Receivable days	122.96	33.55	51.23	103.79	39.93
Inventory Days	118.06	33.80	48.93	79.94	51.78
Payable days	427.20	149.82	205.75	84.78	111.46
Cash Conversion Cycle	-186.17	-82.46	-105.59	98.95	-19.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.